177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)

Clinical trial NCT04315246 · WITHDRAWN

Trial details

NCT number: NCT04315246
Sponsor: Y-mAbs Therapeutics
Status: WITHDRAWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Leptomeningeal Metastasis Solid Tumor, Adult

Start date: 2022-08-31
Primary completion: 2024-12-31
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.